

# ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

~~CIN: U85191DL2011PLC216530~~

Dated: 09.05.2018

~~CIN- L85191DL2011PLC216530~~

|                                                                                                                                                                           |                                                                                                                             |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| <p>The Secretary<br/>National Stock Exchange of India Ltd<br/>Exchange Plaza,<br/>Bandra-Kurla Complex,<br/>Bandra (E),<br/>Mumbai – 400051<br/>Trading Symbol: AGLSL</p> | <p>The Secretary<br/>BSE Ltd<br/>PhirozeJeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai – 400001<br/>Scrip Code: 540616</p> |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|

**Sub: Outcome of the Board Meeting held on May 09, 2018**

Dear Sir/ Madam,

We wish to inform you that Board of Directors of the Company in their meeting held on 09.05.2018 have inter alia approved the following:


1. On recommendation of the Audit Committee, the Board of Directors has approved audited financial results (standalone & consolidated) of the Company under Indian Accounting Standards (IND AS) for the quarter/ year ending March 31, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we are enclosing the following:

- a. Statement showing the audited financial results (standalone & consolidated) of the Company under Indian Accounting Standards (IND AS) for the quarter/ year ending March 31, 2018.
- b. Auditor's report with respect to the audited financial results (standalone & consolidated) of the Company under Indian Accounting Standards (IND AS) for the quarter/ year ending March 31, 2018.

Further, we would like to state that statutory auditors of the Company have issued audit report with unmodified opinion on the statement.

2. The restructuring of the Company and its subsidiary companies i.e Artemis Health Sciences Ltd. ("AHSL"), Artemis Medicare Services Ltd. ("AMSL") and Athena Eduspark Ltd. ("AEL") pursuant to a proposed Composite Scheme of Amalgamation between the Company, AHSL, AEL and AMSL and their respective shareholders and creditors under Section 230 to 232 and other applicable provisions of Companies Act, 2013.



3. The Board of Directors has deferred the decision for redemption of 11% Non-cumulative redeemable preference shares of Rs. 100/- each in Artemis Health Sciences Limited (wholly owned subsidiary).
4. The Board of Directors has authorised Company Secretary to fix date for convening 8<sup>th</sup> Annual General Meeting (AGM) and Record date/Book Closure dates. Accordingly we shall communicate the same.

The Board Meeting commenced at 5.30 p.m. and concluded at 6:55 p.m.

Please take the above information on your records.

Thanking you  
Yours Faithfully

For Artemis Global Life Sciences Limited

  
Anuj Sood  
Company Secretary (A35276)  
D-6/10, 3rd Floor, Rana Pratap Bagh  
New Delhi-110007

**INDEPENDENT AUDITORS' REPORT****THE MEMBERS****ARTEMIS GLOBAL LIFE SCIENCES LIMITED  
(Formerly known as PTL Projects Limited)****Report on the Consolidated Financial Statements**

We have audited the accompanying Consolidated financial statements of HealthCare Global Enterprises Limited ("the Company"), which comprise the Balance Sheet as at 31 March, 2018, and the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the Consolidated financial statements").

**Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Consolidated financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

**Auditor's Responsibility**

Our responsibility is to express an opinion on these Consolidated financial statements based on our audit.

In conducting our audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act, the Rules made thereunder and the Order under section 143 (11) of the Act. We conducted our audit of the Consolidated financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's



judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

### **Emphasis of Matter**

We draw attention to the Note No. 11 in the Notes to the financial statements regarding outstanding liability of Rs. 323.29 lakhs. The amount was recognised as liability in terms of agreement dated 18.01.2011. The amount was subsequently disputed and the dispute was referred to arbitration. The arbitration proceedings are not progressing. The arbitration award is yet to be pronounced.

Our opinion is not modified in respect of this matter.

### **Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31<sup>st</sup> March, 2018, its loss and its cash flows for the year ended on that date.

### **Other Matter**

We did not audit the financial statements of the subsidiary Artemis Health Sciences Limited whose consolidated financial statements reflect total assets of Rs. 47,117.59 Lakhs as at March 31, 2018 and total revenues of Rs. 50,708.61 Lakhs for the year then ended. These consolidated financial statements have been audited by the other auditors whose reports have been furnished to us by the Management, and our opinion is based solely on the reports of the other auditors. Our opinion is not qualified in respect of this matter.

### **Report on other Legal and Regulatory Requirements**

1. As required by section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.



- c. The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account.
- d. In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act.
- e. On the basis of written representations received from the directors as on 31 March, 2018, taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March, 2018, from being appointed as a director in terms of Section 164(2) of the Act.
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in Annexure.
- g. In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014
  - i. The Company does not have any pending litigations which would impact its financial position except arbitration proceedings as explained in para c) of Emphasis of Matters paragraph the impact of which if any, is not ascertained.
  - ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
  - iii. There were no amounts which required to be transferred by the Company to the Investor Education and Protection Fund.

Place: New Delhi

Date: 09 MAY 2018

For Anand Dua & Associates  
Chartered Accountants

FRN: 04263N

  
(Anand Dua)  
Partner  
M. No: 083503

## **Annexure To the Independent Auditor's Report**

### **Report on the Internal Financial Controls under Clause (i) of Subsection 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **Artemis Global Life Sciences Limited (Formerly known as PTL Projects Limited)** ("the Company") as of March 31, 2018 in conjunction with our audit of the Consolidated financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted my our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls Over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.




## Other Matters

The aforesaid reports under section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls over financial reporting in so far as it relates to consolidated financial statements of one subsidiary is based on corresponding report of the auditors of such subsidiary company.

Place: New Delhi

Date: 09 MAY 2018

For Anand Dua & Associates  
Chartered Accountants  
FRN: 04263N



(Anand Dua)  
Partner  
M. No: 083503

**INDEPENDENT AUDITORS' REPORT****THE MEMBERS****ARTEMIS GLOBAL LIFE SCIENCES LIMITED  
(Formerly known as PTL Projects Limited)****Report on the Standalone Financial Statements**

We have audited the accompanying standalone financial statements of HealthCare Global Enterprises Limited ("the Company"), which comprise the Balance Sheet as at 31 March, 2018, and the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

**Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

**Auditor's Responsibility**

Our responsibility is to express an opinion on these standalone financial statements based on our audit.

In conducting our audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act, the Rules made thereunder and the Order under section 143 (11) of the Act. We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the standalone financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's



judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

### **Emphasis of Matters**

- a) We draw attention to the Note No. A-2.19 in the Notes to the financial statements regarding valuation of Preference Shares at cost due to the reason that this item will be eliminated upon consolidation with its subsidiary in the Consolidated Financial Statements. Therefore, the Preference Shares have been valued at cost.
- b) We draw attention to the Note No. 11 in the Notes to the financial statements regarding outstanding liability of Rs. 323.29 lakhs. The amount was recognised as liability in terms of agreement dated 18.01.2011. The amount was subsequently disputed and the dispute was referred to arbitration. The arbitration proceedings are not progressing. The arbitration award is yet to be pronounced.

Our opinion is not modified in respect of these matters.

### **Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31<sup>st</sup> March, 2018, its loss and its cash flows for the year ended on that date.

### **Report on other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2018 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure-A, a statement on the matters Specified in paragraphs 3 and 4 of the Order,
2. As required by section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c. The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account.



- d. In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act except valuation of Preference Shares as referred to in para b) of Emphasis of Matters.
- e. On the basis of written representations received from the directors as on 31 March, 2018, taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March, 2018, from being appointed as a director in terms of Section 164(2) of the Act.
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in Annexure-B
- g. In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014
  - i. The Company does not have any pending litigations which would impact its financial position except arbitration proceedings as explained in para c) of Emphasis of Matters paragraph the impact of which if any, is not ascertained.
  - ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
  - iii. There were no amounts which required to be transferred by the Company to the Investor Education and Protection Fund.

Place: New Delhi

Date: 09 MAY 2018

For Anand Dua & Associates  
Chartered Accountants

FRN: 04263N



(Anand Dua)  
Partner

M. No: 083503

**Annexure referred to in our report to the members of Artemis Global Life Sciences Limited (Formerly known as PTL Projects Limited) for the year ended on March 31, 2018.**

On the basis of the information and explanation given to us during the course of our audit, we report that:

1. (a) The company has maintained proper records showing full including quantitative details and situation of its fixed assets.  
  
(b) As explained to us and as per information provided to us, fixed assets have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification. In our opinion and according to the information and explanations given to us, no fixed asset has been disposed of during the year and therefore does not affect the going concern assumption.  
  
(c) As explained to us and as per information provided to us, the title deeds of immovable properties are held in the name of the company.
2. The company did not have any inventory during the year. Therefore, clause (ii) of the order is not applicable on the company
3. According to the information and explanations given to us and on the basis of our examination of the books of account, the company has not granted any loan, secured or unsecured to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act. Thus, sub clause (a), (b) and (c) of the clause (iii) of the order are not applicable to the company.
4. In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 in respect of loans, investments, guarantees and security.
5. According to the information and explanations given to us and on the basis of our examination of the books of account, the company has not accepted any deposits. Therefore, the directives issued by the Reserve Bank of India and the provisions of sections 73 to 76 or any other relevant provisions of the Companies Act and the rules framed there under, are not applicable to the company. No order has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other tribunal.
6. Maintenance of cost records as specified by the Central Government under sub-section (1) of section 148 of the Companies Act is not applicable to the company.



7. In respect of Statutory Dues:
- a. According to the information and explanations given to us and on the basis of our examination of the books of account, the company is generally regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales-tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities and there were no arrears of outstanding statutory dues as on 31<sup>st</sup> March, 2018 for a period of more than six months from the date they became payable.
  - b. According to the information and explanations given to us and on the basis of our examination of the books of account, there is no amounts payable in respect of income tax or sales tax or service tax or duty of customs or duty of excise or value added tax or cess have not been deposited on account of any dispute.
8. Based on our audit procedures and on the information and explanations given to us, the company has not defaulted in repayment of dues to a financial institution or bank or debenture holders.
  9. The company has not raised any amount by way of initial public offer or further public offer (including debt instruments) and term loans during the year.
  10. According to the information and explanations given to us, no fraud by the company or on the company by its officers or employees has been noticed or reported during the year.
  11. According to the information and explanations given to us and on the basis of our examination of the books of account, the company has neither paid nor provided any managerial remuneration during the year.
  12. According to the information and explanations given to us, the company is not a Nidhi company; therefore, clause (xii) of the order is not applicable.
  13. According to the information and explanations given to us and on the basis of our examination of the books of account, all the transactions with the related parties are in compliance with the sections 177 and 188 of the Companies Act, 2013 and the details have been disclosed in the financial statements as required by the applicable accounting standards.
  14. According to the information and explanations given to us and on the basis of our examination of the books of account, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Therefore, clause (xiv) of the order is not applicable.
  15. According to the information and explanations given to us and on the basis of our examination of the books of account, the company has not entered into any non-cash transactions with directors or persons connected with them.



16. According to the information and explanations given to us and on the basis of our examination of the books of account, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

Place: New Delhi

Date: 09 MAY 2018

For Anand Dua & Associates  
Chartered Accountants

FRN: 04263N



(Anand Dua)  
Partner

M. No: 083503

## **Annexure "B" To the Independent Auditor's Report**

### **Report on the Internal Financial Controls under Clause (i) of Subsection 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **Artemis Global Life Sciences Limited (Formerly known as PTL Projects Limited)** ("the Company") as of March 31, 2018 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted my our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.



## Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- (1) *Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;*
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

## Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


## Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place: New Delhi

Date: 09 MAY 2018

For Anand Dua & Associates  
Chartered Accountants  
FRN: 04263N

  
(Anand Dua)  
Partner  
M. No: 083503

# ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85491DL2041PLC216530

CIN- L85101DL2011FLC216530

| PART I |                                                                                                  | RS. LAKHS     |             |            |                       |            |                         |            |
|--------|--------------------------------------------------------------------------------------------------|---------------|-------------|------------|-----------------------|------------|-------------------------|------------|
| SL.NO. | PARTICULARS                                                                                      | QUARTER ENDED |             |            | STANDALONE YEAR ENDED |            | CONSOLIDATED YEAR ENDED |            |
|        |                                                                                                  | 31.03.2018    | 31.12.2017  | 31.03.2017 | 31.03.2018            | 31.03.2017 | 31.03.2018              | 31.03.2017 |
|        |                                                                                                  | (AUDITED)     | (UNAUDITED) | (AUDITED)  | (AUDITED)             | (AUDITED)  | (AUDITED)               | (AUDITED)  |
| 1      | Revenue from Operations*                                                                         | 10.20         | 10.20       | 10.20      | 40.80                 | 40.80      | 50,278.71               | 46,330.49  |
| 2      | Other Income                                                                                     | -             | -           | -          | -                     | -          | 429.90                  | 631.45     |
| 3      | Total Income from Operations (I+II)                                                              | 10.20         | 10.20       | 10.20      | 40.80                 | 40.80      | 50,708.60               | 46,961.93  |
| 4      | Expenses                                                                                         |               |             |            |                       |            |                         |            |
|        | (a) Purchases of Pharmacy Drugs & Medical Consumables                                            | -             | -           | -          | -                     | -          | 12,083.89               | 11,874.10  |
|        | (b) Purchases of Stock in Trade                                                                  | -             | -           | -          | -                     | -          | 137.15                  | 175.30     |
|        | (c) Change in Inventories                                                                        | -             | -           | -          | -                     | -          | (8.31)                  | (31.76)    |
|        | (d) Employee benefits expense                                                                    | 4.21          | 3.76        | -          | 15.45                 | -          | 942.03                  | 943.02     |
|        | (e) Finance Cost                                                                                 | -             | -           | -          | -                     | -          | 9,068.24                | 8,134.59   |
|        | (f) Depreciation and Amortisation Expense                                                        | 3.72          | 3.85        | 3.68       | 14.74                 | 14.71      | 23,103.62               | 21,061.38  |
|        | (g) Other Expenses                                                                               | 8.51          | 9.99        | 3.70       | 37.43                 | 4.97       | 1,880.56                | 1,549.31   |
|        | Total Expenses (IV)                                                                              | 16.44         | 17.60       | 7.38       | 67.62                 | 19.68      | 47,207.18               | 43,705.94  |
| 5      | Profit / (Loss) from Operations before Exceptional Items and Tax (I-IV)                          | (6.24)        | (7.40)      | 2.82       | (26.82)               | 21.12      | 3,501.42                | 3,255.99   |
| 6      | Exceptional Items**                                                                              | (0.39)        | -           | -          | 10.99                 | -          | 10.99                   | -          |
| 7      | Profit/(Loss) from Ordinary Activities before Tax (5-6)                                          | (5.85)        | (7.40)      | 2.82       | (37.81)               | 21.12      | 3,490.43                | 3,255.99   |
| 8      | Tax Expense                                                                                      | 11.66         | (1.89)      | 1.58       | (7.93)                | 6.31       | 862.80                  | 544.49     |
| 9      | Net Profit/(Loss) from Ordinary Activities after Tax (7-8)                                       | (17.51)       | (5.51)      | 1.24       | (29.88)               | 14.81      | 2,627.63                | 2,711.49   |
| 10     | Extraordinary Items (Net of Tax expenses)                                                        | -             | -           | -          | -                     | -          | -                       | -          |
| 11     | Net Profit/(Loss) for the Period (9-10)                                                          | (17.51)       | (5.51)      | 1.24       | (29.88)               | 14.81      | 2,627.63                | 2,711.49   |
| 12     | Other comprehensive income (net of tax)                                                          |               |             |            |                       |            |                         |            |
|        | A (i) Items that will not be reclassified to profit or loss                                      | -             | -           | -          | -                     | -          | -                       | -          |
|        | (a) Not changes in fair values of investments in equity shares carried at fair value through OCI | -             | -           | -          | -                     | -          | (17.56)                 | (22.03)    |
|        | (b) Deferred tax adjustment on revaluation                                                       | -             | -           | -          | -                     | -          | 14.30                   | 33.56      |
|        | (ii) Income tax related to those items                                                           | -             | -           | -          | -                     | -          | 6.14                    | 7.62       |
| 13     | Total Comprehensive Income                                                                       | (17.51)       | (5.51)      | 1.24       | (29.88)               | 14.81      | 2,630.50                | 2,730.64   |
| 14     | Paid-up Equity Share Capital (Equity Shares of Rs.2/-each)                                       | 1,323.77      | 1,323.77    | 1,323.77   | 1,323.77              | 1,323.77   | 1,323.77                | 1,323.77   |
| 15     | EARNINGS PER SHARE (EPS) (Face Value of Rs. 2/- each)                                            |               |             |            |                       |            |                         |            |
|        | (a) Basic                                                                                        | (0.03)        | (0.01)      | 0.00       | (0.05)                | 0.02       | 3.97                    | 4.10       |
|        | (b) Diluted                                                                                      | (0.03)        | (0.01)      | 0.00       | (0.05)                | 0.02       | 3.97                    | 4.10       |

\* Medical Equipment Lease rentals received from Artemis Medicare Services Ltd.

\*\* Exceptional item of Rs. Rs. 10.99 Lakh represents the expenses incurred towards publishing of statutory advertisement for listing of shares.



Corporate Off : SF 202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon-122002  
Website : www.aglsl.in • E-mail : investor@aglsl.in • Tel. 0124 - 4262305/07 • Fax : 0124 - 4262306

# ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)



Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85194DL2011PLC216530

CIN- L85191DL2011PLC216530

## STANDALONE STATEMENT OF ASSETS AND LIABILITIES

|     |                                             | Rs. In Lakhs            |                         |
|-----|---------------------------------------------|-------------------------|-------------------------|
|     | Particulars                                 | As At<br>March 31, 2018 | As At<br>March 31, 2017 |
| (1) | <b>Assets</b>                               |                         |                         |
|     | <b>Non-current assets</b>                   |                         |                         |
|     | (a) Property, plant and equipment           | 177.36                  | 192.11                  |
|     | (b) Financial assets                        |                         |                         |
|     | i. Investments                              | 15,990.62               | 15,990.62               |
|     | <b>Total non-current assets (A)</b>         | <b>16,167.98</b>        | <b>16,182.72</b>        |
| (2) | <b>Current assets</b>                       |                         |                         |
|     | (a) Financial assets                        |                         |                         |
|     | i. Trade receivables                        | 11.22                   | -                       |
|     | ii. Cash and cash equivalents               | 8.87                    | 51.73                   |
|     | (b) Current tax assets (Net)                | 1.86                    | 0.86                    |
|     | (c) Other current assets                    | 1.32                    | -                       |
|     | <b>Total current assets (B)</b>             | <b>23.27</b>            | <b>52.59</b>            |
|     | <b>Total Assets (A + B)</b>                 | <b>16,191.25</b>        | <b>16,235.31</b>        |
| (3) | <b>Equity and liabilities</b>               |                         |                         |
|     | <b>Equity</b>                               |                         |                         |
|     | (a) Equity share capital                    | 1,323.77                | 1,323.77                |
|     | (b) Other equity                            |                         |                         |
|     | - Reserves & Surplus                        | 14,529.92               | 14,559.81               |
|     | <b>Total equity (C)</b>                     | <b>15,853.69</b>        | <b>15,883.58</b>        |
|     | <b>Liabilities</b>                          |                         |                         |
|     | <b>Non-current liabilities</b>              |                         |                         |
|     | (a) Deferred tax liabilities                | 12.90                   | 23.82                   |
|     | <b>Total non-current liabilities (D)</b>    | <b>12.90</b>            | <b>23.82</b>            |
| (4) | <b>Current liabilities</b>                  |                         |                         |
|     | (a) Provisions                              | 1.02                    | 2.48                    |
|     | (b) Other current liabilities               | 323.64                  | 325.43                  |
|     | <b>Total current liabilities (E)</b>        | <b>324.65</b>           | <b>327.91</b>           |
|     | <b>Total liabilities (F) = (D + E)</b>      | <b>337.56</b>           | <b>351.73</b>           |
|     | <b>Total equity and liabilities (C + F)</b> | <b>16,191.25</b>        | <b>16,235.31</b>        |



Corporate Off : SF 202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon-122002  
 Website : [www.aglsl.in](http://www.aglsl.in) • E-mail : [investor@aglsl.in](mailto:investor@aglsl.in) • Tel. 0124 - 4262305/07 • Fax : 0124 - 4262306

# ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN: U85191DL2011PLC216530

## NOTES:

CIN- L85191DL2011PLC216530

- The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.
- The scheme of arrangement under sections 391 to 394 of the Companies Act, 1956 read with section 230 to 232 Companies Act, 2013 (the Scheme) between Artemis Global Life Sciences Limited (the Company) and PTL Enterprises Limited (the Demerged Company) and their respective shareholders and the creditors of the two companies for demerger of Medicare and Healthcare Services Business undertaking as a going concern into the Company with the Appointed Date at the opening of business hours on 01st April 2016, has been sanctioned by the Hon'ble High Court of Judicature at Kerala vide its Order dated 16th December, 2016, and the Hon'ble National Company Law Tribunal, New Delhi vide its Order dated 1st March, 2017. Certified copies of the order of the Hon'ble High Court of Judicature at Kerala and Hon'ble National Company Law Tribunal, New Delhi have been filed with the Registrar of Companies at Kerala and Delhi respectively and the scheme has become effective from 8th March 2017. Hence, 5,00,000 Equity Shares of Rs 2 (Indian Rupees Two Only) each fully paid up of the Company were Cancelled, and 6,61,88,500 equity shares of Rs. 2 (Indian Rupees Two Only) each were allotted to the shareholder of the Demerged Company on March 30, 2017 in the ratio of 1 (One) equity share in Company for every 1 (One) equity shares of Rs. 2/- (Indian Rupees Two Only) each held in the Demerged Company. Accordingly the paidup capital of the Company is Rs. 1323.77 Lacs.
- The statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under section 133 of the Companies Act 2013, and other recognised accounting practices and the policies to the extent applicable. Being April 1, 2017 company has for the first time adopted Ind AS with the transition date of April 1, 2016.
- Reconciliation of Profit reported in accordance with previous Indian GAAP (IGAAP) to Total Comprehensive Income in accordance


| S.No. | PARTICULARS                              | Rs. Lakhs      |                |                |                |                |
|-------|------------------------------------------|----------------|----------------|----------------|----------------|----------------|
|       |                                          | QUARTER ENDED  |                |                | YEAR ENDING    |                |
|       |                                          | 31.03.2018     | 31.12.2017     | 31.03.2017     | 31.03.2018     | 31.03.2017     |
|       |                                          | (Refer Note 2) | (Refer Note 2) | (Refer Note 2) | (Refer Note 2) | (Refer Note 2) |
|       | Profit for the period as per I GAAP      | (17.51)        | (5.51)         | 1.24           | (29.88)        | 14.81          |
|       | Profit for the period under Ind AS       | (17.51)        | (5.51)         | 1.24           | (29.88)        | 14.81          |
|       | Other Comprehensive income as per Ind AS | -              | -              | -              | -              | -              |
|       | Total Comprehensive income as per Ind AS | (17.51)        | (5.51)         | 1.24           | (29.88)        | 14.81          |

- Reconciliation of equity as per Previous Indian GAAP (I GAAP) and as per Ind AS is given below

| S.No. | PARTICULARS          | Rs. Lakhs        |                  |                  |
|-------|----------------------|------------------|------------------|------------------|
|       |                      | As At 31.03.2018 | As At 31.03.2017 | As At 01.04.2016 |
|       |                      | (Refer Note 2)   | (Refer Note 2)   | (Refer Note 2)   |
|       | Equity as per I GAAP | 15,853.69        | 15,883.58        | 15,868.77        |
|       | Equity as per Ind AS | 15,853.69        | 15,883.58        | 15,868.77        |

- Board of Directors of the Company in their meeting held on 09.05.2018 has approved the restructuring of the Company and its subsidiary companies i.e Artemis Health Sciences Ltd. ("AHSL"), Artemis Medicare Services Ltd. ("AMSL") and Athena Eduspark Ltd. ("AEL") pursuant to a proposed Composite Scheme of Amalgamation between the Company, AHSL, AEL and AMSL and their respective shareholders and creditors under Section 230 to 232 and other applicable provisions of Companies Act, 2013.
- The figures of the last quarter are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter to the current financial year.
- Previous years figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.
- The above results for the quarter and year ended 31st March, 2018 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 9th, 2018. The Statutory Auditors have expressed an unmodified opinion on the aforesaid results.

PLACE: GURUGRAM  
DATE: MAY 9, 2018



For and on behalf of the Board of Directors of  
ARTEMIS GLOBAL LIFE SCIENCES LIMITED



ONKAR S. KANWAR  
CHAIRMAN

Corporate Off : SF 202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon-122002  
Website : www.aglsl.in • E-mail : investor@aglsl.in • Tel. 0124 - 4262305/07 • Fax : 0124 - 4262306

# ARTEMIS GLOBAL LIFE SCIENCES LIMITED


(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

## CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

| Particulars                                 |                  | Rs. In Lakhs   |                  |
|---------------------------------------------|------------------|----------------|------------------|
|                                             |                  | March 31, 2018 | March 31, 2017   |
| (1) <b>Assets</b>                           |                  |                |                  |
| <b>Non-current assets</b>                   |                  |                |                  |
| (a) Property, plant and equipment           | 30,736.33        |                | 28,258.26        |
| Capital work-in-progress                    | 4,317.46         |                | 2,714.80         |
| Intangible assets                           | 292.85           |                | 228.42           |
| Goodwill                                    | 4,162.07         |                | 4,162.07         |
| (b) Financial assets                        |                  |                |                  |
| i. Investments                              |                  |                |                  |
| ii. Loans                                   | 173.96           |                | 246.85           |
| iii. Other financial assets                 | 29.51            |                | 28.21            |
| Non-current tax assets (Net)                | 390.85           |                | 586.07           |
| Other non-current assets                    | 714.22           |                | 1,617.28         |
| <b>Total non-current assets (A)</b>         | <b>40,817.25</b> |                | <b>37,841.96</b> |
| (2) <b>Current assets</b>                   |                  |                |                  |
| Inventories                                 | 644.80           |                | 639.60           |
| (a) Financial assets                        |                  |                |                  |
| i. Trade receivables                        | 5,567.42         |                | 6,066.87         |
| ii. Cash and cash equivalents               | 394.00           |                | 880.01           |
| iii. Bank balances other than (ii) above    | 948.16           |                | 251.26           |
| iv. Loans                                   | 100.80           |                | 39.17            |
| iv. Other financial assets                  | 499.52           |                | 264.68           |
| (b) Current tax assets (Net)                | 16.67            |                | 480.16           |
| (c) Other current assets                    | 724.70           |                | 452.52           |
| <b>Total current assets (B)</b>             | <b>8,896.07</b>  |                | <b>9,074.27</b>  |
| <b>Total Assets (A + B)</b>                 | <b>49,713.32</b> |                | <b>46,916.23</b> |
| (3) <b>Equity and liabilities</b>           |                  |                |                  |
| <b>Equity</b>                               |                  |                |                  |
| (a) Equity share capital                    | 1,323.77         |                | 1,323.77         |
| (b) Other equity                            |                  |                |                  |
| - Reserves & Surplus                        | 25,983.19        |                | 23,352.68        |
| <b>Total equity (C)</b>                     | <b>27,306.96</b> |                | <b>24,676.45</b> |
| <b>Liabilities</b>                          |                  |                |                  |
| <b>Non-current liabilities</b>              |                  |                |                  |
| (a) Financial liabilities                   |                  |                |                  |
| i. Borrowings                               | 5,224.61         |                | 6,569.83         |
| ii. Other financial liabilities             |                  |                | 43.88            |
| (b) Provisions                              | 359.84           |                | 313.81           |
| (c) Deferred tax liabilities                | 1,760.10         |                | 1,574.04         |
| <b>Total non-current liabilities (D)</b>    | <b>7,344.55</b>  |                | <b>8,501.56</b>  |
| (4) <b>Current liabilities</b>              |                  |                |                  |
| (a) Financial liabilities                   |                  |                |                  |
| i. Borrowings                               |                  |                |                  |
| ii. Trade Payables                          | 6,730.71         |                | 6,161.47         |
| iii. Other financial liabilities            | 3,915.96         |                | 2,863.13         |
| (a) Provisions                              | 1,079.34         |                | 1,602.62         |
| (b) Other current liabilities               | 3,335.80         |                | 3,111.00         |
| <b>Total current liabilities (E)</b>        | <b>15,061.81</b> |                | <b>13,738.22</b> |
| <b>Total liabilities (F) = (D + E)</b>      | <b>22,406.36</b> |                | <b>22,239.78</b> |
| <b>Total equity and liabilities (C + F)</b> | <b>49,713.32</b> |                | <b>46,916.23</b> |



Corporate Off : SF 202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon-122002  
 Website : www.aglsl.in • E-mail : investor@aglsl.in • Tel. 0124 - 4262305/07 • Fax : 0124 - 4262306

# ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

## NOTES:

CIN- L85191DL2011PLC216530



- The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.
- The scheme of arrangement under sections 391 to 394 of the Companies Act, 1956 read with section 230 to 232 Companies Act, 2013 (the Scheme) between Artemis Global Life Sciences Limited (the Company) and PTL Enterprises Limited (the Demerged Company) and their respective shareholders and the creditors of the two companies for demerger of Medicare and Healthcare Services Business undertaking as a going concern into the Company with the Appointed Date at the opening of business hours on 01st April 2016, has been sanctioned by the Hon'ble High Court of Judicature at Kerala vide its Order dated 16th December, 2016, and the Hon'ble National Company Law Tribunal, New Delhi vide its Order dated 1st March, 2017. Certified copies of the order of the Hon'ble High Court of Judicature at Kerala and Hon'ble National Company Law Tribunal, New Delhi have been filed with the Registrar of Companies at Kerala and Delhi respectively and the scheme has become effective from 8th March 2017. Hence, 5,00,000 Equity Shares of Rs. 2 (Indian Rupees Two Only) each fully paid up of the Company were Cancelled, and 6,61,88,500 equity shares of Rs. 2 (Indian Rupees Two Only) each were allotted to the shareholder of the Demerged Company on March 30, 2017 in the ratio of 1 (One) equity share in Company for every 1 (One) equity shares of Rs. 2/- (Indian Rupees Two Only) each hold in the Demerged Company. Accordingly the paidup capital of the Company is Rs. 1323.77 Lacs.
- The statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under section 133 of the Companies Act 2013, and other recognised accounting practices and the policies to the extent applicable. Being April 1, 2017 company has for the first time adopted Ind AS with the transition date of April 1, 2016.
- Reconciliation of net profit for the quarter and year ended 31st march 2017 between Ind AS compliant results as reported above with results previously reported (referred to as Previous GAAP) are given below

| S.No. | PARTICULARS                                                                             | RS. LAKHS                 |
|-------|-----------------------------------------------------------------------------------------|---------------------------|
|       |                                                                                         | YEAR ENDING<br>31.03.2017 |
|       | Profit for the period as per I GAAP                                                     |                           |
|       | (a) Employees benefits expense                                                          | 2,711.49                  |
|       | Actuarial (gain)/loss in defined benefit plan transferred to other comprehensive income | 4.94                      |
|       | (b) Finance Cost                                                                        | (16.92)                   |
|       | (c) Other expenses                                                                      | (49.20)                   |
|       | (d) Other operating income                                                              | (11.75)                   |
|       | (e) Tax Expense                                                                         |                           |
|       | MAT Credit Entitlement                                                                  | 903.03                    |
|       | Deferred tax impact on the above Ind AS adjustments                                     | (575.05)                  |
|       | Profit for the period under Ind AS                                                      | 2,966.54                  |
|       | Other Comprehensive income as per Ind AS                                                |                           |
|       | Total Comprehensive income as per Ind AS                                                | 2,966.54                  |

- Reconciliation of equity as per Previous Indian GAAP (I GAAP) and as per Ind AS is given below

| S.No. | PARTICULARS                                          | RS. LAKH                  |
|-------|------------------------------------------------------|---------------------------|
|       |                                                      | YEAR ENDING<br>31.03.2017 |
|       | Equity as per I GAAP                                 |                           |
|       | Fair valuation of security deposits                  | 24,312.74                 |
|       | Fair valuation of long term liabilities / borrowings | (4.70)                    |
|       | For deferred tax (liability) / assets                | (0.32)                    |
|       | Fair valuation of loans & advances                   | (1,446.99)                |
|       | For reversal of lease equalisation reserve           | 3.54                      |
|       |                                                      | 496.04                    |
|       | Tax impact on OCI components                         |                           |
|       | Remeasurement of post employment benefit obligations | (7.62)                    |
|       | Equity as per Ind AS                                 | 23,352.69                 |

- Previous years figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.



Corporate Off : SF 202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon-122002  
 Website : www.aglsl.in • E-mail : investor@aglsl.in • Tel. 0124 - 4262305/07 • Fax : 0124 - 4262306

# **ARTEMIS GLOBAL LIFE SCIENCES LIMITED**

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN- ~~U85191DL2011PLC216530~~

CIN- L85191DL2011PLC216530

- 7 The above results for the quarter and year ended 31st March, 2018 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 9th, 2018. The Statutory Auditors have expressed an unmodified opinion on the aforesaid results.

For and on behalf of the Board of Directors of  
ARTEMIS GLOBAL LIFE SCIENCES LIMITED

*Onkar Kanwar*

ONKAR S. KANWAR  
CHAIRMAN

PLACE: GURUGRAM  
DATE: MAY 9, 2018

